# Gilead Sciences (GILD) net assets (shareholders' equity)

URL: https://funkfolio.com/stock/GILD/net-assets

> Gilead Sciences (GILD) net assets (shareholders' equity) were $22.70B at the end of fiscal 2025, up 17.4% from fiscal 2024. Five-year growth: 4.5% a year.

---

## Gilead Sciences (GILD) net assets (shareholders' equity)

**Net assets · fiscal 2025:** $22.70B at Dec 31, 2025

Gilead Sciences (GILD) had net assets of $22.70B at the end of fiscal 2025 (December 31, 2025). That is 17.4% higher than the $19.33B of fiscal 2024. Figures as of 18 Nov 2026, 20:50 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Net assets, fiscal 2025:** $22.70B
- **Change on fiscal 2024:** +17.4%
- **Growth, 5 years:** +4.5% a year
- **Growth, 10 years:** +2.0% a year
- **Highest on record:** $22.83B fiscal 2023
- **Lowest on record:** $3.75B fiscal 2007
- **Fiscal years on record:** 19 2007–2025

Figures as of 18 Nov 2026, 20:50 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Gilead Sciences net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 4.5% a year; over ten years the rate was 2.0% a year. Across the 19 fiscal years on record (2007–2025), the highest was $22.83B in fiscal 2023 and the lowest $3.75B in fiscal 2007.

### Net assets by fiscal year

### Gilead Sciences net assets (shareholders' equity), year by year

Gilead Sciences (GILD) net assets (shareholders' equity) by fiscal year

| Fiscal year | Net assets | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | $22.70B | 17.4% up | Dec 31, 2025 |
| 2024 | $19.33B | 15.3% down | Dec 31, 2024 |
| 2023 | $22.83B | 7.5% up | Dec 31, 2023 |
| 2022 | $21.24B | 0.8% up | Dec 31, 2022 |
| 2021 | $21.07B | 15.8% up | Dec 31, 2021 |
| 2020 | $18.20B | 19.2% down | Dec 31, 2020 |
| 2019 | $22.53B | 5.3% up | Dec 31, 2019 |
| 2018 | $21.39B | 4.6% up | Dec 31, 2018 |
| 2017 | $20.44B | 8.2% up | Dec 31, 2017 |
| 2016 | $18.89B | 1.9% up | Dec 31, 2016 |
| 2015 | $18.53B | 20.1% up | Dec 31, 2015 |
| 2014 | $15.43B | 35.7% up | Dec 31, 2014 |
| 2013 | $11.37B | 22.2% up | Dec 31, 2013 |
| 2012 | $9.30B | 38.0% up | Dec 31, 2012 |
| 2011 | $6.74B | 14.9% up | Dec 31, 2011 |
| 2010 | $5.86B | 7.9% down | Dec 31, 2010 |
| 2009 | $6.37B | 49.0% up | Dec 31, 2009 |
| 2008 | $4.27B | 13.9% up | Dec 31, 2008 |
| 2007 | $3.75B | — | Dec 31, 2007 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

### How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

### Net assets at health care companies of similar size

Net assets of Gilead Sciences and comparable companies

| Company | Net assets | Fiscal year |
| --- | --- | --- |
| [Thermo Fisher Scientific TMO](https://funkfolio.com/stock/TMO/net-assets) | $53.41B | 2025 |
| [Amgen AMGN](https://funkfolio.com/stock/AMGN/net-assets) | $8.66B | 2025 |
| Gilead Sciences GILD | $22.70B | 2025 |
| [Abbott Laboratories ABT](https://funkfolio.com/stock/ABT/net-assets) | $52.13B | 2025 |
| [Novo Nordisk NVO](https://funkfolio.com/stock/NVO/net-assets) | DKK 194.05B | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Gilead Sciences, figure by figure

- [Gilead Sciences market cap](https://funkfolio.com/stock/GILD/market-cap)
- [Gilead Sciences revenue](https://funkfolio.com/stock/GILD/revenue)
- [Gilead Sciences earnings](https://funkfolio.com/stock/GILD/earnings)
- [Gilead Sciences earnings per share (EPS)](https://funkfolio.com/stock/GILD/eps)
- [Gilead Sciences P/E ratio](https://funkfolio.com/stock/GILD/pe-ratio)
- [Gilead Sciences P/S ratio](https://funkfolio.com/stock/GILD/ps-ratio)
- [Gilead Sciences P/B ratio](https://funkfolio.com/stock/GILD/pb-ratio)
- [Gilead Sciences free cash flow](https://funkfolio.com/stock/GILD/free-cash-flow)
- [Gilead Sciences operating margin](https://funkfolio.com/stock/GILD/operating-margin)
- [Gilead Sciences dividend](https://funkfolio.com/stock/GILD/dividend)
- [Gilead Sciences shares outstanding](https://funkfolio.com/stock/GILD/shares-outstanding)
- [Gilead Sciences total debt](https://funkfolio.com/stock/GILD/total-debt)
- [Gilead Sciences cash on hand](https://funkfolio.com/stock/GILD/cash)
- [Gilead Sciences total assets](https://funkfolio.com/stock/GILD/total-assets)
- [Gilead Sciences total liabilities](https://funkfolio.com/stock/GILD/total-liabilities)
- [Gilead Sciences return on equity (ROE)](https://funkfolio.com/stock/GILD/roe)
- [Gilead Sciences return on invested capital (ROIC)](https://funkfolio.com/stock/GILD/roic)

[Gilead Sciences (GILD) overview: price, valuation and scorecard](https://funkfolio.com/stock/GILD) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Gilead Sciences net assets (shareholders' equity): questions and answers

**What are Gilead Sciences's net assets?**

Gilead Sciences (GILD) had net assets of $22.70B at the end of fiscal 2025 (December 31, 2025). That is 17.4% higher than the $19.33B of fiscal 2024.

**What is the growth rate of Gilead Sciences's net assets?**

Over the five fiscal years to 2025 net assets grew at a compound 4.5% a year; over ten years the rate was 2.0% a year.

**What are the highest and lowest net assets figures on record for Gilead Sciences?**

Across the 19 fiscal years on record (2007–2025), the highest was $22.83B in fiscal 2023 and the lowest $3.75B in fiscal 2007.

**How is Gilead Sciences's net assets calculated?**

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Gilead Sciences it is on record here for 19 fiscal years, 2007 to 2025.

Fiscal years are named for the calendar year they end in.

### Learn: net assets (shareholders' equity)

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Market cap vs enterprise value: what is the difference?](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

  Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Gilead Sciences (GILD) net assets (shareholders' equity)”, data as of 18 November 2026. https://funkfolio.com/stock/GILD/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.
